Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Cellestia Biotech AG currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, FOWLER, ALAN JEROME, and is housed within 1 distinct art unit. The data shows a highly focused prosecution profile with no distribution across multiple units or officials. This concentration suggests that the company's current biotechnology filings are being evaluated within a specific technical niche, allowing for a consistent examination process.
FOWLER, ALAN JEROME is the busiest examiner with 1 pending office action. Since there is only 1 pending action for the company, this examiner oversees all current active matters. The placement in 1 art unit indicates that the company's innovations are being reviewed by a single specialized group at the USPTO. For the practitioner, this means that the prosecution strategy can be tailored to the specific preferences of this 1 examiner. The success of the company's current pharmaceutical portfolio depends entirely on the resolution of this 1 pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FOWLER, ALAN JEROME | 1 | 100.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18566618 | Method for Treating an Autoimmune and Inflammatory Disease | FOWLER, ALAN JEROME | — |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18566618 | Method for Treating an Autoimmune and Inflammatory Disease | FOWLER, ALAN JEROME | 1691 | §102§103§112 | Non-Final OA | — | Pending | Dec 01, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial